Latest News

3rd International Conference on Lipid Science & Technology

3rd International Conference on Lipid Science & Technology December 11-12, 2017 Rome, Italy Venue: Holiday Inn…

International Atherosclerosis Research School August 20th – 25th, 2017 Prague, Czech Republic

International Atherosclerosis Research School August 20th – 25th, 2017 Prague, Czech Republic   Up close and…

21th Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis | Call for Abstract Submission

The Israeli Society for Research, Prevention and Treatment of Atherosclerosis invites you to submit your research…

International Atherosclerosis Research School – applications opened

iARS 2016: application opened! International Atherosclerosis Research School Hamburg, Germany, from August 21st to 27th, 2016…

FH awareness week – What is FH?

September 24 is FH-awareness day. All this week, in a series of newsletters, EAS will highlight…

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Expert consensus on the rational clinical use of proprotein  convertase subtilisin/kexin type 9 (PCSK9) inhibitors Abstract Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. These fully human…

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Calculation of the possibility of Familial Hypercholesterolemia using the Dutch criteria:…

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management…

The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease

The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease V.D. Raikou, D. Kyriaki…

Effect of thrombin on human endothelial progenitor cells

Effect of thrombin on human endothelial progenitor cells HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 Effect of thrombin on human endothelial progenitor cells S. Papadaki, S. Sidiropoulou, V. Chantzichristos, M. Paschopoulos, A. Tselepis…

The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study.

The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study. HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study. Ch. Kotoulas, I. Mamarelis, E. Koutoulakis, M.…

Atherosclerosis as a risk factor for dementia and Alzheimer’s disease

Atherosclerosis as a risk factor for dementia and Alzheimer’s disease HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 Atherosclerosis as a risk factor for dementia and Alzheimer’s disease V. Zacharopoulou, G. Zacharopoulou , K. Karkoulias, E. Tsampalas A. Lazakidou…

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European…

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Introduction Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately associated with myocardial infarction, a significant proportion of…

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

PREFACE The American College of Cardiology (ACC) develops a number of clinical policy documents to provide members with guidance…

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This…

Joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

Joint consensus  statement from the European Atherosclerosis  Society and European Federation of Clinical  Chemistry and Laboratory Medicine

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points.…

Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias.

Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias.

  Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias. Publication in full here…

2016 European Guidelines on cardiovascular disease prevention in clinical practice

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Published in 2016 Reference 2016 EHJ doi/10.1093/eurheartj/ehw106 The Sixth Joint Task Force of the European Society of Cardiology…

Consensus Statement of the European Atherosclerosis Society on Lipoprotein(a) as a cardiovascular risk factor

Consensus Statement of the European Atherosclerosis Society on Lipoprotein(a) as a cardiovascular risk factor

The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second,…

Consensus Statement of the European Atherosclerosis Society on Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.

Consensus Statement of the European Atherosclerosis Society on Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.

Abstract Objective: This EAS Consensus Panel critically appraised evidence relevant to the benefit to risk relationship of functional…

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).

The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in…

Photos
  • 6th Symposium of the Working Groups, 4 & 5/12/2015, Divani – Caravel, Athens

    6th Symposium of the Working Groups, 4 & 5/12/2015, Divani – Caravel, Athens

    View All

  • 23d Scientific Meeting, “Multifaceted treatment of Cardiovascular Danger” | Nafplio, Greece

    23d Scientific Meeting, “Multifaceted treatment of Cardiovascular Danger” | Nafplio, Greece

    View All

  • 24th Scientific Meeting: “Prevention and Treatment of Cardiovascular Disease” | Chalkidiki, Greece

    24th Scientific Meeting: “Prevention and Treatment of Cardiovascular Disease” | Chalkidiki, Greece

    View All

  • 2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy | Kos Greece

    2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy | Kos Greece

    View All

  • 8th Summer School (25 – 27/6/2015)

    8th Summer School (25 – 27/6/2015)

    View All